- Home
- NCNA vs PRFX Comparison
NCNA vs PRFX Comparison
Compare NCNA & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- PRFX
- Stock Information
- Founded
- NCNA 1997
- PRFX 2007
- Country
- NCNA United Kingdom
- PRFX Israel
- Employees
- NCNA N/A
- PRFX N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- PRFX Health Care
- Exchange
- NCNA Nasdaq
- PRFX Nasdaq
- Market Cap
- NCNA 3.4M
- PRFX 3.0M
- IPO Year
- NCNA 2017
- PRFX 2020
- Fundamental
- Price
- NCNA $0.97
- PRFX $2.30
- Analyst Decision
- NCNA Buy
- PRFX Hold
- Analyst Count
- NCNA 2
- PRFX 1
- Target Price
- NCNA $25.00
- PRFX N/A
- AVG Volume (30 Days)
- NCNA 118.8K
- PRFX 46.2K
- Earning Date
- NCNA 05-15-2025
- PRFX 01-01-0001
- Dividend Yield
- NCNA N/A
- PRFX N/A
- EPS Growth
- NCNA N/A
- PRFX N/A
- EPS
- NCNA N/A
- PRFX N/A
- Revenue
- NCNA N/A
- PRFX N/A
- Revenue This Year
- NCNA N/A
- PRFX N/A
- Revenue Next Year
- NCNA N/A
- PRFX N/A
- P/E Ratio
- NCNA N/A
- PRFX N/A
- Revenue Growth
- NCNA N/A
- PRFX N/A
- 52 Week Low
- NCNA $0.69
- PRFX $0.43
- 52 Week High
- NCNA $10.79
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- NCNA 48.38
- PRFX 36.25
- Support Level
- NCNA $0.81
- PRFX $2.12
- Resistance Level
- NCNA $1.34
- PRFX $2.79
- Average True Range (ATR)
- NCNA 0.14
- PRFX 0.17
- MACD
- NCNA 0.02
- PRFX -0.04
- Stochastic Oscillator
- NCNA 29.20
- PRFX 21.69
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.